SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines.
Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct of self-improvement.
We use Artificial Intelligence to bring therapeutic solutions to the patients without a time-consuming and ineffective R&D process.
- Area of Activity
- Technology transfer
- Research services and supplies
- Research network
- Science - Technology parks
- Manufacture of biotech equipment
- Drug discovery
- Research Centers
- Company type
- Services and consulting for biotech sector
- Public and Private Organizations - Non Profit Centers - Medical Research Facilities
- Industrial Biotechnology - Manufacturers
- Health Biotechnology
- Technology Services
The SOM Biotech team is made up of 11 talented people with experience in the discovery and development of medicines, always driven by curiosity, excellence and a personal development instinct.
- Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO
- Núria Reig, PhD CHIEF SCIENTIFIC OFFICER
- Saurabh Mishra, MBA CHIEF FINANCIAL OFFICER
- Santi Esteva, PhD CLINICAL OPERATIONS MANAGER
- Oscar Huertas, MSc DRUG DISCOVERY MANAGER
- Gal·la Pericot, MSc R&D MANAGER
- Aileen Ferré, MSc SCIENTIST
- Luca Signorile, PhD SENIOR COMPUTATIONAL CHEMIST
- Mireia Prat, BA OFFICE MANAGER
- Gerard Jorba, BSc, PGDip SCIENTIST
- Maria Zimina, PhD, MBA BUSINESS DEVELOPMENT MANAGER
The pipeline of SOM Biotech mainly contains programs focused on Orphan indications.
All programs are obtained through the proprietary AI-based technology.
Chorea movements associated with Huntington’s disease
SOM3355 is an oral VMAT2 inhibitor (vesicular monoamine transporter 2) for the symptomatic treatment of chorea movements associated with Huntington’s disease (HD), and other hyperkinetic movement disorders. SOM3355 is currently in Phase 2a trials in HD and has shown a favorable safety profile with no depression effects. You can find more information about Clinical trials for SOM3355 here NCT03575676.
Huntington’s disease is an inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. Huntington’s disease has a broad impact on a person’s functional abilities and usually results in movement, thinking (cognitive) and psychiatric disorders.
SOM1311 is a small molecule pharmacological chaperone of Phenylalanine Hydroxylase for the treatment of Phenylketonuria.
Phenylketonuria (PKU) is is characterized by an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated, PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders.
Niemann–Pick type C
SOM0208 is a small molecule for the treatment of Niemann–Pick C disease.
Niemann–Pick type C is a lysosomal storage disorder caused by defects in the intracellular transport and metabolism of cholesterol and glycolipids. The disease has a broad clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen or liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth.